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Attached or Available as Indicated 
 
1. BELMONT REPORT  
Based on the Nuremberg Trials, these principles set universal standards for 
research.  All Assurance Statements and Agreements provide for adherence to the 
Belmont Report.  Available at http://ohsr.od.nih.gov/guidelines/guidelines.html.   
 
2. FEDERALWIDE ASSURANCE 
The CORRC is a federally registered Institutional Review Board (IRB) and has an 
approved Federal wide Assurance (FWA00000324).  A national registry of 
approved IRBs may be found at http://www.hhs.gov/ohrp.   
 
3. RESEARCH REGULATIONS 
All research must be carried out in accordance with federal and state research 
regulations.  DMH regulations are consistent with federal regulations, but, in many 
cases, DMH research regulations are more restrictive than the federal regulations.  
Regulations are available on line at: 
Federal Regulations 45 CFR 46: http://ohsr.od.nih.gov/guidelines/guidelines.html 
State Regulations 104 CMR 31.00: www.mass.gov/dmh 
 
4. DEPARTMENT RESEARCH GUIDELINES (by request) 
• PLACEBO CONTROLS 
• ADVERSE EVENT REPORTING 
• RESEARCH INVOLVING CHILDREN, FORENSIC PATIENTS AND/OR 
PREGNANT WOMEN AS SUBJECTS. 
 
5. UNAFFILIATED INVESTIGATOR AGREEMENT (attached) 
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6. DEPARTMENT OF MENTAL HEALTH PERIODIC REVIEW FORM 
(attached) 
 
7. ROSTER OF CORRC MEMBERS (by request) 
 
8. HIPAA COMPLIANCE ADDENDUM FOR CONSENT FORMS (attached) 
 
9. ADVERSE EVENT REPORTING FORM (attached)  
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COMMONWEALTH OF MASSACHUSETTS 
DEPARTMENT OF MENTAL HEALTH 
CENTRAL OFFICE RESEACH REVIEW COMMITTEE 
PRINCIPAL INVESTIGATOR’S PACKAGE 
 
 
PART A. BASIC INFORMATION ABOUT THE DMH CENTRAL 
OFFICE RESEARCH REVIEW COMMITTEE 
 
 
I.   CENTRAL OFFICE RESEARCH REVIEW COMMITTEE (CORRC) 
 
The CORRC is the federally registered Institutional Review Board (Registration 
No. IORG0000186) of the Department of Mental Health (DMH).  It has an 
approved Federalwide Assurance (FWA00000324).  The CORRC operates 
pursuant to M.G.L. c. 12, §1 and 104 CMR 31.03.  The DMH Commissioner 
appoints the CORRC members.  The chairs of the CORRC report to the Deputy 
Commissioner of Clinical and Professional Services.   
 
Standards and procedures applicable to and applied by CORRC include the 
following:  
 
(a) The Commonwealth of Massachusetts Department of 
Mental Health Federalwide Assurance for Institutions 
within the United States; (See Attachments) 
(b) Title 45 of the Code of Federal Regulations (CFR), Part 46 
(45 CFR 46); 
(c) The National Commission for the Protection of Human 
Subjects of Biomedical and Behavioral Research report 
entitled: Ethical Principles and Guidelines for the 
Protection of Human Subjects of Research (the “Belmont 
Report”); 
(d) DMH regulations 104 CMR 1.00, et. seq. (See 
Attachments); 
(e) DMH policies; 
(f) DMH research guidelines issued by the Commissioner or 
the Deputy Commissioner of Clinical and Professional 
Services (See Attachments); and 
(g) The Operating Procedures for the Central Office Research 
Review Committee. 
 
 
II.  RESEARCH SUBJECT TO REVIEW BY THE CORRC 
 
All research, regardless of funding source, must be reviewed by the CORRC if: 
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(a) A DMH employee, as an employee, participates as a 
research investigator or a subject; 
(b) A DMH client is a subject of the research, unless the 
research in no way is related to DMH, or a facility or 
program operated or contracted for by DMH; 
(c) The research involves disclosure of data by DMH; or 
(d) The terms of an agreement or other regulations require 
CORRC review. 
 
104 CMR 31.01 Authority and Scope. 
 
Inquiries as to whether a project falls within the parameters of 104 CMR 31.01 
should be made to Jeffery Burke, Co-chair of the CORRC. 
 
If 104 CMR 31.01 is applicable, the research cannot be conducted unless reviewed 
and approved by the CORRC.  Additionally, no such research may be conducted 
unless the DMH Commissioner, or designee, determines that the research will 
promote the mission of DMH. 
 
 
III.  PURPOSE 
 
The purpose of the research review is to protect human subjects from research 
risks.  All potential risks must be identified and procedures to reduce those risks 
must be specified.  Evaluation of the scientific merit of the study (e.g., peer review) 
is not the primary charge of the CORRC, and it is assumed that the Principal 
Investigator has undertaken such a scientific review before the protocol is 
submitted to the CORRC.  However, the CORRC may disapprove a proposal if it 
determines that it is not scientifically sound.  
 
 
IV.  PRINCIPLES OF REVIEW 
 
The following principles guide the review process. 
 
(a) The proposed research design is sound and involves no unnecessary 
research risks. 
(b) Any risks are reasonable and in relation to the benefits. 
(c)  Risks to subjects are identified and minimized. 
(d) Subject selection is equitable. 
(e) Informed consent is obtained. 
(f)  Additional safeguards exist for vulnerable subjects. 
(g)  Privacy and confidentiality are maximized. 
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V.  MEETINGS 
 
The CORRC meets regularly, generally the first Wednesday of every month, at 
noon, at the DMH Central Office, 25 Staniford Street, Boston, MA.  Investigators 
are invited to attend meetings to discuss their research.  CORRC meetings are open 
to the public, but votes taken by the CORRC are taken in executive session. 
 
 
VI. PROPOSAL SUBMISSION 
 
Researchers must submit a written proposal to the CORRC to review.  The 
proposal must conform to the Research Proposal section of this Principal 
Investigator’s Package (Part E).  Sixteen (16) copies of a proposal (all materials 
with the exception of the detailed technical supplemental materials, such as external 
protocols, for which five (5) copies are sufficient) must be submitted for review.   
However, email submission of documents is encouraged, and materials submitted 
as email attachments do not need to be submitted as hard copies.   
 
The Principal Investigator should first submit a single set of materials to 
Jeffrey Burke, Co-chair of the CORRC, as soon as the materials are ready.  
The materials will be reviewed and the Principal Investigator will be contacted 
to discuss whether the proposal is ready for submission to the full committee.  
Do not submit 16 copies without this prior review.   
 
It takes approximately five to six weeks from submission of a proposal for 
preliminary review to the final CORRC action.  The CORRC usually votes on 
research proposals on the day they are presented, provided that sufficient materials 
are submitted and further consultation is not necessary.  Written confirmation of the 
CORRC’s decision is made promptly. 
 
VII. DRAFT PROPOSALS 
 
While researchers are invited to discuss research issues with either of the CORRC 
chairs, the CORRC does not formally review draft proposals and will only approve 
or disapprove a formal research proposal.  All materials must be in a final form 
before review by the full committee.   
 
Students must obtain the approval of their advisors prior to submitting a proposal to 
the CORRC.  A signed written approval from the student’s advisor must be 
submitted with the proposal. 
 
VIII. CORRC APPROVAL 
 
Following review and approval of the submitted materials, CORRC will provide 
the Principal Investigator with a letter of approval.  The consent form and any 
flyers or public documents will be given a date-stamp approval.   
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Research activities must not begin prior to full approval.  Only approved 
documents may be used.  Any subsequent changes to the procedures of the study 
cannot be implemented until the documentation is updated and re-approved by the 
CORRC.   
 
IX. MONITORING 
 
Subsequent to approval by the CORRC, the CORRC will monitor the progress of 
the research.  A monitoring schedule will be set forth in the approval letter.  At a 
minimum, a project will be monitored once a year, or if the project is less than one 
year, once during the duration of the research.   
 
The CORRC works in conjunction with an Area Research Monitoring Committee, 
established in each DMH Area, and provides information about research studies to 
that Committee.  That Committee may contact the Principal Investigator and 
request additional information.  From time to time, the CORRC will send to the 
Principal Investigator a CORRC Periodic Review Form that the Principal 
Investigator must complete and return to the CORRC by the time and date 
specified.  Failure to do so may result in suspension or termination of the 
research.  A copy of the Department Periodic Review Form is attached 
(Attachment 6). 
 
The CORRC may require additional progress reports and/or may conduct 
additional audits of the research to ensure that it is being conducted in compliance 
with the approved protocol. 
 
NO CHANGES TO THE PROTOCOL, THE INFORMED CONSENT FORM, OR 
MATERIALS ASSOCIATED WITH THE PROJECT, MAY BE MADE 
WITHOUT THE PRIOR APPROVAL OF THE CORRC.  
 
Any serious adverse events involving human subjects must be reported promptly to 
the CORRC (Attachment 9).  
 
X. REVIEWS BY OTHER INSITUTIONAL REVIEW BOARDS 
 
The Department may enter into Cooperative Research with other Federally 
registered Institutional Review Boards with approved Federal wide Assurances.  
However, proposals will always be subject to CORRC review, because DMH 
regulations impose requirements in addition to those imposed by federal law. 
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PART B.   CORRC CONTACT INFORMATION. 
 
 
The CORRC meets on a regular basis on the first Wednesday of each month.  Meetings are 
held in the Chelsea Room of the Erich Lindemann Mental Health Center from noon to 2:00 
PM.  Meetings are open to the public, and investigators are urged to attend the meeting in 
order to respond to questions and discuss issues with the Committee during the review.   
 
Investigators should contact Jeffrey Burke to discuss procedures for scheduling a review.   
Any protocol needs to be pre-reviewed by one of the co-chairs before it is brought to the 
full committee.  The co-chairs are available for technical assistance at any point during the 
preparation of a research protocol.   
 
 
 
 
MAILING ADDRESS:  
 
   Jeffrey Burke, Co-Chair 
  Central Office Research Review Committee (CORRC) 
Department of Mental Health 
167 Lyman Street 
Westborough, MA  01581 
 
 
TELEPHONE NUMBER: (508) 616-3502 
 
 
FAX NUMBER: (617) 616-3599 
 
 
E-MAIL ADDRESS:  Jeffrey.burke2@massmail.state.ma.us 
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PART C. CHECKLIST FOR CENTRAL OFFICE RESEARCH 
REVIEW COMMITTEE SUBMISSION 
 
All research must support the mission of the Department of Mental Health.  The following 
Documents are required for all research proposals. 
 
I. RESEARCH PROPOSAL SUMMARY (See Page 8) 
 
This is a brief, one-to-two page summary of the important points of the proposed 
research written in lay language.   
 
It also must include a statement as to how this research will promote the mission of  
DMH.   The mission of DMH is to improve the quality of life for adults with 
serious and persistent mental illness and children with serious mental illness or 
severe emotional disturbance.  This is accomplished by ensuring access to an 
integrated network of effective and efficient and culturally competent mental health 
services that promotes consumer rights, responsibilities, rehabilitation, and 
recovery.   DMH is also charged with conducting research into the causes of mental 
illness.   
 
II. RESEARCH PROPOSAL (See Page 9) 
 
This is a specific and detailed description of the proposed research, addressing the 
questions contained in this package.  Research protocols supplied by external 
parties, such as sponsoring corporations, are not adequate as they do not address 
issues of specific site implementation and all issues of concern to human subjects.  
External protocols may be included as an attachment; generally only five copies are 
required.  The CORRC approves only specific and well-defined proposals; it does 
not give blanket authorization for preliminary or undefined topic areas. 
 
III. INFORMED CONSENT FORM (See Page 16) 
 
The specific consent form(s) to be used in the project must be supplied to the 
CORRC.  Consent forms in languages other than English, if applicable, should be 
included.  The form(s) should follow the guidelines set forth in Guidelines for the 
Informed Consent Form in this package (Part F).  The CORRC is available to 
provide technical assistance and consultation before, during, and after the initiation 
of a project. 
 
IV. COPIES OF ALL TESTS, QUESTIONNAIRES, OR OTHER 
NON-STANDARD INSTRUMENTS TO BE USED 
 
If an instruments is standardized and well-known (e.g., SCID, CGI), a copy is not 
required. 
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V. COPIES OF ALL LETTERS, SCRIPTS, POSTERS, NOTICES, FLYERS, 
WRITTEN MATERIALS AND ADVERTISEMENTS TO BE USED FOR 
SUBJECT RECRUITMENT. 
 
VI. BRIEF RESUMES OF THE PRINCIPAL INVESTIGATOR AND 
CO-PRINCIPAL INVESTIGATORS. 
 
VII. PROOF OF EACH INVESTIGATOR’S COMPLETION OF TRAINING IN 
THE PROTECTION OF HUMAN SUBJECTS.  An on-line training system is 
available at http://ohsr.od.nih.gov/, or investigators may complete a local facility 
training that meets the NIH standards.  
 
VIII. DULY EXECUTED UNAFFILIATED INVESTIGATOR AGREEMENT 
FOR EACH INVESTIGATOR WHO IS NOT AN EMPLOYEE OF DMH.  
See the attachments for a copy of the form. 
 
IX.   HIPAA ADDENDUM TO THE INFORMED CONSENT FORM.  HIPAA 
regulations impose strict requirements around the use of Personal Health 
Information.  If these requirements are included in an addendum, rather than 
included in the consent form, then the HIPAA addendum must be attached.   
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PART D. THE RESEARCH PROPOSAL SUMMARY 
 
A Research Proposal Summary must be included in the materials submitted to the 
CORRC.  THE CORRC will furnish a copy of the Research Proposal Summary to the 
Commissioner and/or the Deputy Commissioner of Clinical and Professional Services 
during the pre-approval stage and to all applicable DMH Area Director(s) and Area 
Medical Directors after the study is approved.  
 
The Research Proposal Summary is a one-to-two page summary that provides the 
following information using bullet points and a minimum of text: 
 
1. Submission date 
 
2. Project title 
 
3. Source of funding, including institutional or corporate sponsor and protocol 
references 
 
4. Principal Investigator(s), degree(s) and affiliation(s), telephone number, address, 
and email address 
 
5. Brief description of the project including: 
 
(a) Overview and purposes; 
(b) Methods and procedures; 
(c) Subjects – numbers, description, and inclusion criteria; 
(d) Data to be recorded; and 
(e) Start date and duration of study. 
 
6. DMH Area(s), facilities and program site(s) that will be involved in the research. 
 
7. Potential risks to subjects 
 
8. Potential benefits to subjects 
 
9. A statement of how the research will promote the mission of the Department of 
Mental Health 
 
10. Other IRBs involved. 
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PART E. THE RESEARCH PROPOSAL 
 
The Research Proposal provides a complete overview of the site-specific project in a 
format that directly answers questions relevant to the CORRC.  Protocols provided by a 
sponsoring corporation should be provided to the CORRC, but do not replace the Research 
Proposal required by this Part E.  The Research Proposal must provide specific 
information about how the protocol will be implemented at each site. The Committee is 
especially interested in the methods of subject identification, contact, recruitment and 
monitoring. 
 
Each page of the Research Proposal must be consecutively numbered and include the 
submission or revision date. The narrative should be brief and succinct, but the essential 
points must be clearly indicated.   
 
The Research Proposal must contain the following information. 
 
1. Submission Date / Version Date 
 
2. Project Title. 
 
3.  Funding/Sponsor 
 
 Identify the source of funding or sponsor for the study, including protocol number. 
 
4. Principal Investigator(s)  
 
Identify the investigator(s) conducting the research, their organizational affiliations, 
contact information and credentials.  Briefly summarize prior research by the 
principal investigator in this field. 
 
5. Location(s)  
 
Identify the DMH Area, facility and program location(s) where the project will be 
conducted.  Include the program name(s), and also the name(s), telephone 
number(s) and address(es) of the person(s) in charge of the program at the stated 
location(s).  If the PI has had contact with these entities prior to CORRC approval, 
explain in detail.  
 
6. Subjects 
 
Describe the subjects to which access is sought.  Include relevant information on 
expected gender, ethnicity, and age groups of subjects.  Address the subjects' 
expected state of mental and physical health. Summarize exclusion and inclusion 
criteria. 
 
Identify how many subjects will be recruited.  If this is a multi-site study, 
identify the total number of subjects to be recruited and the number at this site.   
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Describe in detail the process of identifying and contacting potential subjects, 
recruiting them into the study, obtaining consent, determining competency to 
give consent, and monitoring their well-being during and after the study. How 
will potential subjects be identified?  How and by whom initial contact with 
potential subjects will be made?  Describe the consent process and monitoring 
procedures to ensure that subjects’ well-being is adequately addressed.  This is one 
of the critical steps that the CORRC will review intensively.   
 
Attach any written materials that will be used, such as posters or 
advertisements, or letters to DMH staff.  If contact will be made by telephone or 
interview, attach a script or outline of the intended communication.   
 
7. Research Methods and Procedures   
 
This section should provide the reviewers with a clear overview of the proposed 
research.  Comprehensive project descriptions may also be attached, e.g., protocols 
developed by (or for) sponsoring organizations or developed for academic 
purposes.  However, the CORRC needs a specific description of procedures that 
will be followed at the research site.  Literature should be attached only to the 
extent that it conveys to the CORRC potential scientific merit and/or contribution 
to the field. 
 
A suggested format for this section includes: 
 
 Specific Aims and Purposes: State the specific aims and objectives of the 
research, including hypotheses.  Describe how the proposed research relates to the 
mission of the Department of Mental Health. 
 
Methods and Procedures:  Describe in detail the steps that will be taken to 
conduct the research.  Often a chart showing meetings and action steps such as 
evaluations is helpful.  It is important to understand the research project from the 
perspective of the subject.   
 
Data to be Recorded:  List and describe all data, including laboratory tests, 
evaluations, questionnaires, and forms.   If data will be recorded from existing 
records, specify the data elements and what records will be accessed.  If laboratory 
tests will be performed, list the tests.   
 
Be specific about the source of the data, when the data will be recorded, the forms 
that will be used and the conditions under which data will be recorded.  Explain 
which members of the research team will record, have access to and/or process the 
data.   
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Start Date and Duration of the Study: State the duration of the research, 
including how long a subject will be involved in the project, and the overall 
duration of the entire study. 
 
8.  Assessment of Risk to Subjects 
 
From the subject's perspective, identify all foreseeable risks, including physical, 
psychological, social, economic, legal or other, and their likelihood and potential 
severity.  Loss of confidentiality or privacy is considered to be a serious research 
risk in any study.  Describe all steps that will be taken to minimize all identified 
risks and discomforts.  
 
Describe steps taken to minimize the loss of confidentiality or privacy.  Describe 
procedures to ensure that subject participation in the study and responses to study 
procedures are kept confidential.  Describe where data will be kept, whether it is 
locked, and who has access to the data, and how long the data will be kept.   
 
9. Procedures for Monitoring Subjects’ Well-Being 
 
 Describe procedures for monitoring the well being of subjects and procedures to be 
followed if there is any adverse effect to a subject during or upon termination of the 
research.  If this is a drug study, describe how the clinical status of the subject will 
be monitored, including the clinical staff.  Describe procedures to ensure that the 
well-being of individual subjects takes precedence over the requirements of the 
study design.   
 
10.  Care and Treatment Statement 
 
  Describe how the care and treatment of subjects may be affected during and after 
the research. 
 
11. Informed Consent (See Part F) 
 
 Describe the intended informed consent procedures and attach the Informed 
Consent Form(s) that will be used.  Describe how the clinical determinations that 
each subject has the capacity to give informed consent will be done in compliance 
with 104 CMR 31.05(c). 
 
12. Benefits 
 
 Describe the expected benefits of the research to the subjects and the potential 
benefits to others.   Note – it is expected that most research projects do not provide 
a likelihood of personal benefit to individual subjects.   Also note that 
compensation for participation is not a benefit.   
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13. Remuneration, Costs and Reimbursements 
 
 State how subjects will be compensated for their participation.  Describe any 
foreseeable financial costs to subjects and what reimbursement, if any, subjects will 
receive to offset such costs. 
 
14. Explain why the research requires the participation of persons with mental 
illness. 
 
 
15. Safeguards for Confidentiality  
 
 Describe safeguards for maintaining confidentiality of the data collected, including 
the manner of data disposal at the termination of the research.  Special procedures 
may be needed for forms of data that cannot easily be made anonymous, such as 
photographs, videotapes or audiotapes. 
 
16. Final Product(s) 
 
 Describe the intended final product, its intended use and manner of dissemination 
or publication.  Describe publication agreements and ownership of the data.  Will 
the data be available for subsequent research?  Does the PI intend to contact 
subjects in the future for follow up studies?  Note that re-use of data or research 
subjects for future projects is not permitted unless sought in advance and 
separately requested.  Intended re-contact should be documented in the procedures 
and consent form.     
 
 Indicate any intentions to establish copyright, patents, or similar rights and identify 
all interested parties in such rights. 
 
17. Financial Summary 
 
 Provide a financial summary of the project’s financing, including the funding 
source and amount of funding for the research.  Explain the mechanism for receipt 
of funding and how investigators are compensated (e.g., being paid based on the 
number of subjects recruited). Explain any relations between the investigators and 
the sponsor.  These relationships may include compensation for teaching, travel, 
stock ownership, ownership of any entity contracting to perform or monitor the 
research, or the relationship of any member of the investigator’s immediate family.      
 
18. Compensation for Injuries 
 
 Describe any medical treatment and/or financial compensation available to the 
subject in case of injury.  Indicate if any investigator will serve a dual role with any 
subject (e.g., treating physician, therapist, social worker). 
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19. Insurance 
 
 Describe any insurance (type, amount, and purpose) that the principal investigator, 
or other, intends to purchase for the project.  Describe any of the subject’s 
insurance or entitlements that may be invoked.   
 
20. Use of DMH Resources 
 
 Describe the manner in which any DMH resources will be used in conducting the 
research and any expected compensation to DMH or its employees.  
 
21. Other IRBs Involved 
 
 List any other agencies or committees that have reviewed or will be requested to 
review this study.  Attach any approval letters obtained from other IRBs.  Has the 
proposed research been rejected by an agency for reasons other than funding 
availability? 
 
22. Adverse Events 
 
 Define “Adverse Event” for purposes of the study and describe the plan for 
identifying, grading and reporting such events to the CORRC or other entities.  
(See, the attached DMH Guidelines for Adverse Event Reporting.) 
 
23. Required Attachments 
 
(a) Resume of the Principal Investigator(s) 
(b) For each investigator proof of completion of the Federal Office for Human 
Research Protections’ training for researchers.  Currently on-line at: 
http://ohsr.od.nih.gov/. 
(c) For each investigator who is not an employee or an agent of DMH, a duly 
signed Unaffiliated Investigator Agreement (See, attached). 
 
24. Attachments that are appropriate, when applicable: 
 
(a) Approval Form(s) from other IRBs that have reviewed this project. 
(b) Copies of non-standardized questionnaires, instruments, tests, etc. 
(c) Copies of posters, flyers, letters, etc. 
(d) Scripts of intended communications by telephone or interview. 
(e) External research protocols (usually, only five (5) copies are required of the 
technical drug research protocols - check with the CORRC before 
submitting materials). 
 
March 1, 2011 
Division of Clinical and Professional Services 
Central Office Research Review Committee 
14
 
ADDITIONAL INSTRUCTIONS FOR SPECIFIC TYPES OF RESEARCH PROJECTS 
 
A. Projects involving drugs 
 
1. Describe fully the drugs (or other substances) to be used, side effects and 
interactions. 
(a) Fully describe the drug and results of relevant safety and effectiveness 
research. 
(b) Indicate the dosage to be used and the established dosage parameters and 
the procedures for establishing individual clinically effective dosages. 
(c) Indicate whether a federal IND is required. 
 
2. Describe fully the procedures to be used in ensuring subjects' well-being during 
critical phases of the project. 
(a) Describe the wash-out period for existing drugs and the phase-in period for 
the new drugs.  Procedures for monitoring subjects during these critical 
times must include face-to-face monitoring by a qualified person on a daily 
basis.  Will this be done by research staff or primary treaters?   
(b) Describe procedures for ensuring the security of the storage of the drug and 
dispensing the drug. 
(c) The investigational drug may turn out to be less effective than the drug that 
was discontinued.  This is a potential risk that must be indicated to the 
subject. 
(d) Indicate if the new drug will be made available to the subject at the 
termination of the study. 
(e) At the termination of the study, if the new drug is discontinued and another 
drug, typically the old drug, is started, item (a) above is applicable again. 
 
 
B. Projects involving placebos.   DMH Guidelines for Studies that Involve Placebo Controls 
are available upon request. 
 
1. It must be demonstrated that the study is appropriate for placebo controls.  
2. The benefits must outweigh the risks to subjects; 
3. The selection criteria set forth in the guidelines must be met. 
4. The protocol must demonstrate that the required study procedures set forth in the 
guidelines have been incorporated in full. 
 
C. Projects involving children or individuals under guardianship.   DMH Guidelines for 
Studies that Involve Children, Forensic Patients or Pregnant Women as Subjects are 
available upon request. 
 
1. Specifically describe the need to use children as research subjects, and why 
"normal" children or adolescents cannot be used. 
2. Describe the procedures for obtaining assent from research subjects when parents or 
guardians have legal authority in the matter.  If a waiver is requested, explain why.   
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3. Describe the Principal Investigator's prior experience with this population. 
4. Specify which categories of risks listed in the Guidelines are applicable to the study.  
 
D. Projects involving forensic patients.  DMH Guidelines for Studies that Involve Children, 
Forensic Patients or Pregnant Women as Subjects are available upon request. 
 
1. Specify which of the four types of permissible research apply to the protocol.  
2. Explain how the risks involved in the research are commensurate with the risks that 
would be accepted by other participants who are not forensic patients. 
3. Explain how the selection process, informational materials, and the plans for 
follow-up care, meet the requirements of the guidelines. 
 
E. Project involving pregnant women.   DMH Guidelines for Studies that Involve Children, 
Forensic Patients or Pregnant Women as Subjects are available upon request. 
 
1. Specify how the research falls into one or more of the categories of “allowed 
research” as specified in the guidelines. 
2. Describe the procedures for obtaining consent from both the mother and father, if 
applicable.  Explain if special monitoring of the consent process has been planned, if 
not, why is it not considered necessary? 
 
F. Projects involving special equipment, devices, or special procedures. 
 
1. Describe the equipment, the environment, and from a subject's perspective, what 
will happen on a step-by-step basis. 
2. Indicate whether the procedures will be available to the subjects after the project is 
concluded. 
 
G. Projects involving access to medical or other records 
 
1. Indicate the physical location where the records will be kept. 
2. List the specific data elements that will be recorded.  Attach all recording forms. 
3. Indicate who will review the records and who will have access to the data. 
4.   Describe the steps that will be taken to protect confidentiality of the data (e.g., 
recording code numbers instead of names). 
5.   The Informed Consent Form must clearly describe to the subject that permission is 
being requested to review specific records for the purpose of recording specific 
data elements. 
 
H. Federally sponsored research. 
 
1.   Provide a copy of all applicable federal regulations and guidelines. 
2.   Specify all required federal signatories and the status of obtaining such signatures. 
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PART F. THE INFORMED CONSENT FORM  104 CMR 31.05 (5) 
 
The consent process is intended to educate potential subjects about the research project and 
request their voluntary participation.  A verbal explanation of the project, with discussion 
and questions, is important in augmenting the written consent form.  The Informed 
Consent Form is a guide to this process and is the written record that the subject entered 
the study voluntarily and with full understanding of the research project.   
 
Since each research project is different, there is no generic Informed Consent Form.    
However, this document provides a description of required sections and the specific 
required information that is required in each section.  Suggested language, that the 
researcher may modify as needed, is indicated in italicized text.  
 
In developing a consent form for a specific research project, please note the following 
points: 
 
• It must provide full and complete information about the project, organized 
carefully so that the specific sections, described below, are covered thoroughly. 
 
• It must be written in language that is understandable without using jargon or 
technical language. 
 
• The language should be written in the second person, so as to avoid any undue 
sense of coercion for potential subjects.  The final Statement(s) of Consent, 
however, should be written in the first person. 
 
• The degree of detail, and the length of the consent form, should reflect the level 
of risk that the project entails for the subject. 
  
Informed Consent and HIPAA 
 
HIPAA requires that research subjects sign an Authorization Form, which is a permission 
document that permits the covered entity to use/disclose Protected Health Information 
(PHI) for anything other than treatment, payment or health care operations.   
 
Authorization for PHI Uses and Disclosures 
 
A valid Privacy Rule Authorization is an individual's signed permission that allows a 
covered entity to use or disclose the individual's PHI for the purpose(s) and to the 
recipient(s) stated in the Authorization. When an Authorization is obtained for research 
purposes, the Privacy Rule requires that it pertain only to a specific research study, not to 
future, unspecified projects. If an Authorization for research is obtained, a covered entity's 
uses and disclosures must be consistent with what is stated in the Authorization.  
 
An Authorization differs from an informed consent in that an Authorization is an 
individual's permission for a covered entity to use or disclose his or her PHI for a certain 
purpose, such as a research study. An informed consent, on the other hand, is the 
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individual's permission to participate in the research. An informed consent provides 
research subjects with a description of the study and of its anticipated risks and/or benefits, 
and a description of how the confidentiality of records will be protected, among other 
things. An Authorization can be combined with an informed consent document or other 
permission to participate in research. Whether combined with an informed consent or 
separate, an Authorization must contain the specific core elements and required statements 
stipulated in the Privacy Rule.  
 
Authorization Core Elements  
• A description of the PHI to be used or disclosed, identifying the information in a 
specific and meaningful manner.  
• The names or other specific identification of the person or persons (or class of 
persons) authorized to make the requested use or disclosure.  
• The names or other specific identification of the person or persons (or class of 
persons) to whom the covered entity may make the requested use or disclosure.  
• A description of each purpose of the requested use or disclosure.  
• Authorization expiration date or expiration event that relates to the individual or to 
the purpose of the use or disclosure ("end of the research study" or "none" are 
permissible for research, including for the creation and maintenance of a research 
database or repository).  
• Signature of the individual and date. If the individual's legally authorized 
representative signs the Authorization, a description of the representative's 
authority to act for the individual must also be provided.  
Authorization Required Statements 
• A statement of the individual's right to revoke his/her Authorization and how to do 
so, and, if applicable, the exceptions to the right to revoke his/her Authorization or 
reference to the corresponding section of the covered entity's notice of privacy 
practices.  
• Whether treatment, payment, enrollment, or eligibility of benefits can be 
conditioned on Authorization, including research-related treatment and 
consequences of refusing to sign the Authorization, if applicable.  
• A statement of the potential risk that PHI will be re-disclosed by the recipient and 
no longer protected by the Privacy Rule. This may be a general statement that the 
Privacy Rule may no longer protect health information disclosed to the recipient.  
 
The web site listed below may be used to reference this text as well as a general overview 
of Clinical Research and the HIPAA Privacy Rule.   
http://privacyruleandresearch.nih.gov/clin_research.asp 
 
Investigators have a choice between developing a HIPAA-compliant consent form in 
which the required language is contained within the consent form, or using a HIPAA 
addendum which is a separate document that subjects must read and sign.   
Investigators should check with their local institution of affiliation for guidance.  
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INFORMED CONSENT FORM 
 
 
1.      HEADING 
 
Study Title 
Title of the Study 
Corporate Sponsor of the Study 
Principal Investigator 
Principal Investigator, with telephone and email address 
Associated Investigators, with telephone and email addresses 
Institution of Affiliation 
 
2.      PURPOSE 
 
The study must be described in clear user-friendly language.  It must be stated that this is 
a research project, and the purposes and objectives of the study should be explained.  If 
the subject is being recruited because of specific clinical characteristics, this must be 
stated. 
 
The source of funding for the project should be identified.  If a corporate sponsor or a grant 
funds the study, the subject must be informed of this.   
 
3.      PROCEDURES 
 
The specific steps that will be followed must be spelled out in sufficient detail that the subject 
is aware of all aspects of his/her involvement with the project.  Procedures that are 
experimental, i.e., non-routine, must be identified.   
 
The total number of research subjects, in total and at this site, and the number of sites, must be 
stated.   
 
Potential subjects must be informed of the nature of the data that will be recorded about them.  
A description of the data to be recorded, the sources of the data, how the data will be stored 
and steps taken to preserve confidentiality, the parties that will have access to the data, and 
how long the data will be kept must be described.  The degree of detail should be based on the 
degree of risk, the extent to which the procedures are not routine, and the degree of sensitive or 
personal issues involved.  HIPAA definitions of Protected Health Information that should be 
considered include: 
 
 Laboratory tests, 
 Results from standardized instruments or rating scales, 
 Results from locally-developed instruments or rating scales,  
 Data from the subject’s chart or medical record, 
 Clinician’s or Case Manager’s assessments  
 Demographic characteristics. 
 
The duration of each step of the project should be given, as well as the duration of the 
overall project.   
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If the study involves treatment, alternative procedures or courses of treatment that could be 
used instead of the experimental procedures should be described.   
 
Where relevant: 
 
 “You will be receiving treatment as a part of this research study.  You or your 
insurance company will [not] be charged or held responsible for the costs of that 
care.”  
 
 “All study-related costs associated with your being in this research project will be 
paid for by [sponsor name].   
 
4.      RISKS AND DISCOMFORTS 
 
Any foreseeable risks and/or discomforts must be described in detail.   
 
Risks may include loss of confidentiality, statutory duty to disclose information (mandated 
reporting), disruption of ongoing treatment, potential ineffectiveness of experimental treatment, 
side effects of experimental medications, etc. 
 
Discomforts may include fatigue, recall of unpleasant experiences, travel to the study site, etc. 
 
Procedures for minimizing risk or managing bad outcomes should be described, as well as 
proposed medical treatment and/or financial compensation in case of injury. 
 
If new information becomes available that may change the risks, or might change your 
decision to be in this research project, you will be notified in a timely fashion.   
 
5.      BENEFITS AND SIGNIFICANCE 
 
Direct, personal benefits to the subject as a consequence of participation should be described.  
Remuneration is not considered to be a benefit and is described in Section 7.   Many research 
studies do not have the potential for direct personal benefit for participants. 
 
Possible benefits for others that may result as a consequence of the study may be described. 
 
6.      CONFIDENTIALITY 
 
The means by which confidentiality of data and the anonymity of the subject will be 
protected during and after the study must be described in detail.  Specific details must 
include: 
 what data elements will be recorded and the sources of those data elements,  
 how and where the data will be stored (e.g., in a locked file in the researcher’s 
office),  
 what personal identifying data will be recorded,  
 whether the research data are entered into the subject’s permanent medical record,  
 how and when data will be destroyed,  
 how reports will be written (e.g., “no individuals will be identified”). 
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Researchers cannot promise absolute confidentiality, since research records are subject 
to court subpoenas or inspection by research monitoring authorities.  In addition, the 
investigator may be a mandated reporter for suspected instances of abuse.  Suggested 
language: Confidentiality will be protected to the extent allowed by the law.  For 
example, if we determine from information that you provide that any other person is at 
risk or may have been abused, we may be required to notify the appropriate 
authorities.  If this were to happen, we would discuss this with you.    
 
Other parties that may have access to the research records and the purpose of their 
access must be stated: Research records that identify you and the consent form signed 
by you may be looked at for regulatory purposes by: 
 The sponsor, 
 The U.S. Food and Drug Administration (if appropriate), 
 Agencies of the U.S. Department of Health and Human Services, and 
 The Central Office Research Review Committee (CORRC), DMH Area Monitoring 
Committees, or their designees.  The CORRC is a group of people appointed by the 
Commissioner of the Department of Mental Health to perform independent reviews 
of research. Area Monitoring Committees are established in each DMH Area under 
the Area Medical Director to work with the CORRC in monitoring ongoing 
approved research projects.     
 
If the data to be recorded falls under HIPAA regulations as Protected Health 
Information, the subject has the right to review any data that is collected about 
him/hers:  “You have the right to review any data that is recorded about you.”  
Specific exceptions to this requirement, such as blinded drug trials, should be 
described.   
 
The retention period for the research records must be specified: “The study results will 
be retained in your research record [for six years or until after the study is completed, 
whichever is longer].  At that time either the research information not already in your 
medical record will be destroyed or information identifying you will be permanently 
removed from the study results.  Any research information in your medical record will 
be kept indefinitely.”   
 
If the data sought are particularly sensitive or if procedures make it possible that 
sensitive information might be revealed to the researcher, more specific language is 
required.  For example, if there is a risk that a subject may disclose information about 
abuse, appropriate language would be: “We are required to report abuse or threats to 
harm others to appropriate authorities.  If that were to happen, we would discuss this 
with you.” 
 
 
7.      REMUNERATION 
 
The amount of money that will be paid to the subject must be stated.  Other forms of 
compensation, such as coupons, should be described.  If the subject will not be 
compensated for their participation, that must be stated. 
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8.      SERVICES AND RELATIONSHIPS TO THE DEPARTMENT 
 
It must be clearly stated that: Your participation is voluntary and independent of care 
and treatment.  Any services received now or in the future will not be affected by your 
decision to participate or not to participate.  You may withdraw from the study at any 
time without any impact on services you receive now or in the future.   
 
The potential subject should be told clearly that if an adverse event occurs, the 
researcher is required to make a report to the sponsor and to the CORRC.  In addition, 
the subject’s medical record may need to be reviewed, depending on the event:  “If an 
adverse event occurs, we may need to review your entire medical record.  All data that 
have been already collected for study purposes, and any new information about an 
adverse event related to the study, may be sent to the study sponsor.”   
 
In an inpatient study, practical limitations on immediate withdrawal and discharge 
should be described.  For example, “If you are an inpatient when you decide to 
withdraw, the study doctor will evaluate your clinical condition and decide whether 
you require continued hospitalization or transfer to other services.” 
 
9.      VOLUNTARY PARTICIPATION/WITHDRAWAL 
 
Your participation in this study is completely voluntary.  You may decide not to 
participate in this study.  If you do participate, you may freely withdraw from the study 
at any time.  The Department of Mental Health does not urge or encourage anyone 
associated with DMH to take part in a research project.  Your decision not to participate 
or to withdraw from the study will have no effect whatsoever on any services or benefits 
you receive.   
 
Your participation in this study may be stopped at any time by the study staff, without 
your consent, if they feel that it is in your best interest, or if you do not comply with the 
study procedures.   
 
10. INQUIRIES 
 
If you have questions or want to discuss the research study, you may contact: the name 
and local telephone number of the investigator should be given. 
 
If you have questions or want to discuss your rights as a research subject, you may 
contact: the name and local telephone number of the local or on-site Human Rights 
Officer or Consumer Advocate should be given. 
 
 
 
11. CONSENT STATEMENT AND SIGNATURES 
 
This section should begin with a statement to the potential subject: Do not sign this 
consent form unless you have had a chance to ask questions and have received 
satisfactory answers to all your questions. 
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This section should include a consent statement that the subject fully understands all 
aspects of the study, has had the opportunity to ask questions, and consents voluntarily to 
participate.  The subject must be given a copy of the signed Informed Consent Form.   
 
A sample Consent Statement is:  “I have read this consent form and the purpose of this 
study, including procedures to be followed and the risks and benefits, which have been 
explained to me.  I have been allowed to ask questions, and my questions have been 
answered to my satisfaction.  I have been told whom to contact if I have additional 
questions.   
 
I voluntarily consent to be in this study with the understanding that I may withdraw at 
any time.  
 
I have been told that I will be given a signed copy of this consent form. 
 
By signing this consent form, I have not waived any of the legal rights which I 
otherwise would have as a subject in a research study.” 
 
Subject’s Signature and date.  If the project includes multiple procedures, such as 
review of medical records or contact with family members, it is advisable to have the 
subject sign separately for each procedure or release of information.   
 
If the subject is a minor, the parents or legal guardian may consent in place of the subject.  
If the subject is an adult and not competent, a legal guardian may give consent if legally 
authorized.  In these cases, the study must not proceed without the subject’s assent and 
cooperation. 
 
Investigator’s Signature and date.  The investigator or representative who presented the 
consent process must sign a statement that s/he has explained the study and provided 
opportunity for questions.  Additionally, a member of the research staff must document 
that s/he made a clinical determination that the subject had the capacity to give 
informed consent. 
 
Witness’s signature and date.  The CORRC or the Principal Investigator may determine 
that an independent witness is necessary because of special risks.  The witness should 
sign a statement that the consent process was reasonable and voluntary.   
 
12. DETERMINATION OF COMPETENCE AND UNDERSTANDING 
 
The burden is on the Principal Investigator to document that the subject is competent, i.e., 
has the capacity to understand the research project, that the subject understands what is 
involved by participating, and that the subject agreed to participate voluntarily, i.e., 
without coercion.   
 
One option is to provide a brief statement that attests to these three criteria, with the 
signature and date of the person making the attestation.   
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Another option is to include a brief, True-False quiz about the study to the subject with 
the requirement that all questions must be answered correctly and all other criteria 
satisfied before the consent form can be signed.   
 
 
 
 
 
 
March 1, 2011 
Division of Clinical and Professional Services 
Central Office Research Review Committee 
24
 
PART G.   RESPONSIBILITIES OF THE PRINCIPAL INVESTIGATOR 
 
 
The Principal Investigator is responsible for obtaining approval for the proposed project before 
any work is initiated. Failure to do this, or the performing of recruitment or research without 
obtaining CORRC approval, is a serious offense under both federal and state regulations. 
 
In addition to obtaining CORRC approval for the proposed project, the Principal Investigator also 
has the following ongoing obligations to the CORRC: 
 
 
I. TRAINING 
 
The Principal Investigator will complete any training required by DMH or the CORRC. 
 
II. PERIODIC REVIEW 
 
Federal and state regulations require that an approved project must be monitored on an 
ongoing basis, at least once each year, or if shorter, once during the protocol’s duration.  If 
the CORRC approves a research protocol, it will establish a monitoring schedule for that 
protocol.   
 
The CORRC works in conjunction with an Area Monitoring Committee established in 
each DMH Area and shares information about research studies with that Committee.  In 
turn, the Area Monitoring Committee may contact the Principal Investigator and request 
additional information.   
 
As part of any monitoring, the CORRC will mail to the Principal Investigator a Periodic 
Review Form (a copy of this form is attached) for completion by the Principal Investigator 
by the date specified by the CORRC.  Additionally, the Informed Consent Form must also 
be re-approved and date-stamped as part of any monitoring scheduled by the CORRC. 
 
 
III. NOTIFICATION OF SERIOUS ADVERSE EVENTS 
 
The Principal Investigator must report to the designated Co-Chair of the CORRC within 
twenty-four hours all “Serious Adverse Events” as that term is defined in the DMH 
Guidelines for Reporting Adverse Events or by the CORRC for purposes of the protocol.  
Additionally, the Principal Investigator must report to the designated Co-Chair of the 
CORRC all other “Adverse Events” as that term is defined in the DMH Guidelines for 
Reporting Adverse Events, or by the CORRC for purposes of the protocol, at such times as 
is designated in the Guidelines, or if different as the CORRC designates.  
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IV. ONGOING CHANGES IN THE APPROVED PROTOCOL OR FORMS 
 
Periodically, changes in an approved protocol or forms may be necessary.  Before 
implementing these changes, they must be approved by the CORRC or by the Co-Chairs if 
they determine that the changes are not substantive and do not require a review by the full 
CORRC. 
 
The CORRC must be notified of changes in a protocol, consent form, or documentation in 
writing, and clean copies of the new forms must be provided.  The CORRC will then issue 
an updated approval letter for the study as well as any other required documentation (e.g., 
re-stamped consent form).   
 
V. NOTIFICATION OF TERMINATION OF THE PROJECT 
 
The CORRC and DMH Area Monitoring Committee need to know when a project is 
formally ended. The Periodic Review Form may be used for this purpose.  Copies of 
publications resulting from the project are not required, but a bibliography of such 
materials is important. 
 
 
VI. RESEARCH STANDARDS 
 
The Principal Investigator is responsible for reviewing the following standards and for 
ensuring that his or her research protocol is in compliance with such standards at all times.  
The Belmont Report: Ethical Principles and Guidelines for the Protection of Human 
Subjects of Research; the U.S. Department of Health and Human Services (DHHS) 
regulations for the protection of human subjects at 45 CFR 46; the DMH Federalwide 
Assurance, and the relevant DMH regulations, policies, guidelines and procedures for the 
protection of human subjects; including but not limited to, 104 CMR 31.00.  In addition, 
the Principal Investigator is responsible for complying with all other national, state, or 
local laws or regulations that may provide additional protection for human subjects.  The 
Principal Investigator’s primary responsibility is to safeguard the rights and welfare of 
each research subject, and the subject’s rights and welfare must take precedence over the 
goals and requirements of the research. 
 
VII. DETERMINATIONS OF THE CORRC AND APPROPRIATE DMH OFFICIALS 
 
The Principal Investigator must abide by all determinations of the CORRC and must 
accept the final authority and decisions of the CORRC, including but not limited to 
directives to terminate participation in designated research activities. Similarly, the 
Principal Investigators must abide by the determinations of certain DMH officials as 
specified in the DMH research regulations, 104 CMR 31.00, et. Seq. and procedures.   The 
Principal Investigator must provide all information requested by DMH or the CORRC in a 
timely fashion and must cooperate in any audit conducted by either and complete such self-
assessments as may be requested.  
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VIII. INFORMED CONSENT 
 
The Principal Investigator will seek, document, and maintain records of informed consent 
from each subject or the subject’s legally authorized representative as required under 
DHHS and DMH regulations and as stipulated by the CORRC.  The Principal Investigator 
will not enroll subjects in the research prior to the proposal’s approval by the CORRC.  All 
consent forms and procedures must be compliant with HIPAA policies and regulations.   
 
IX. FDA-REGULATED PRODUCTS 
 
In conducting research involving FDA-regulated products, the Principal Investigator will 
comply with all applicable FDA regulations and fulfill all Principal Investigator 
responsibilities (or Investigator-sponsor responsibilities, where appropriate), including 
those described at 21 CFR 312 and 812. 
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ATTACHMENT 1 
 
UNAFFILIATED INVESTIGATOR AGREEMENT 
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Commonwealth of Massachusetts 
Department of Mental Health 
Unaffiliated Research Investigator Agreement 
 
Name of Institution Providing IRB Oversight: 
OHRP Federal wide Assurance Number: 
Name of Unaffiliated Investigator: 
Department Research Review Committee File No.: 
 
(1) The above-named Unaffiliated Investigator has reviewed the Belmont Report: Ethical 
Principles and Guidelines for the Protection of Human Subjects Research; the U.S. 
Department of Health and Human Services (DHHS) regulations for the protection of human 
subjects at 45 CFR 46, and relevant Commonwealth of Massachusetts Department of Mental 
Health (Department) regulations, policies, guidelines and procedures for the protection of 
human subjects; including but not limited to, 104 CMR 31.00. 
 
(2) The Investigator understands and hereby accepts the responsibility to comply with the 
standards and requirements stipulated in the above documents and to protect the rights and 
welfare of human subjects involved in research conducted under this Agreement.   
 
(3) The Investigator will comply with all other National, State, or local laws or regulations that 
may provide additional protection for human subjects.   
 
(4) The Investigator will abide by all determinations of the Department’s Research Review 
Committee designated under the above Assurance and will accept the final authority and 
decisions of the Department’s Research Review Committee, including but not limited to 
directives to terminate participation in designated research activities.  
 
(5) The Investigator will complete any training required by the Department or the Department’s 
Research Review Committee prior to initiating research covered under this Agreement.  
 
(6) The Investigator will report promptly to the Chair of the Department’s Research Review 
Committee proposed changes in the research conducted under this Agreement.  The 
investigator will not initiate changes in the research without prior Research Review Committee 
review and approval, except when necessary to eliminate immediate hazards to subjects.  
 
(7) The Investigator will report immediately to the Chair of the Department’s Research Review 
Committee any unanticipated problems in research covered under this Agreement that involves 
risks to subjects or others.  
 
(8) The Investigator will seek, document, and maintain records of informed consent from each 
subject or the subject’s legally authorized representative as required under HHS and 
Department regulations and as stipulated by the Department’s Research Review Committee. 
 
(9) The Investigator acknowledges and agrees to cooperate in the Department’s and the 
Department’s Research Review Committee’s responsibility for initial and continuing review, 
record keeping, reporting, and certification.  The Investigator will provide all information 
requested by the Department and the Department’s Research Review Committee in a timely 
fashion. 
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(10) In conducting research involving FDA-regulated products, the investigator will comply with 
all applicable FDA regulations and fulfill all investigator responsibilities (or investigator-
sponsor responsibilities, where appropriate), including those described at 21 CFR 312 and 812. 
 
(11) The Investigator will not enroll subjects in research under this Agreement prior to its review 
and approval by the Department’s Research Review Committee. 
 
(12) Emergency medical care may be delivered without the Research Review Committee’s review 
and approval to the extent permitted under applicable Federal regulations and State law.  
However, such medical care may not be included as part of Federally-supported research. 
 
(13) The Agreement does not preclude the Investigator from taking part in research not covered 
under the Agreement. 
 
(14) The Investigator acknowledges that her/his primary responsibility is to safeguard the rights 
and welfare of each research subject, and that the subject’s rights and welfare must take 
precedence over the goals and requirements of the research. 
 
 
Signatures: 
 
Investigator: ______________________________________________ Date: _______________ 
 
Department Official: _______________________________________ Date: _______________ 
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ATTACHMENT 2 
 
DEPARTMENT OF MENTAL HEALTH PERIODIC REVIEW FORM 
 
 
 
 
 
 
 
 
 
 
COMMONWEALTH OF MASSACHUSETTS 
DEPARTMENT OF MENTAL HEALTH  
CENTRAL OFFICE RESEARCH REVIEW COMMITTEE 
PERIODIC REVIEW FORM 
 
CORRC Tracking Number:       
 
Principal Investigator(s):           
 
Address:             
              
Telephone Number:            
 
Title of Project:             
 
I. PROJECT STATUS (check one) 
 
  The project did not start and is not in operation.  (Skip all questions below, sign and 
date the form.) 
 
  The project did not start but is expected to start during the next year.  (Complete the 
form, sign and date it and include a clean copy of the planned Consent Form.) 
 
  The project is ongoing and open to enrollment. (Complete the form, sign and date it 
and include a clean copy of the Consent Form currently being used.) 
 
  The project is ongoing but is closed to enrollment.  (Complete the form, sign and date 
it and include a clean copy of the Consent Form currently being used.) 
 
   The project concluded on     (inset date), which was after 
the date of the last Periodic Review by CORRC. (Complete the form, sign and date it 
and attach a summary of the results, and.) 
 
II. RESEARCH PROJECT SPECIFIC: 
 
1. Since approval or the last Periodic Review, whichever was later,           (insert a 
number) human subjects were studied. 
 
1A.  How many human subjects are currently participating in the study?  
 
1B.  How many human subjects have participated since the study began?    
 
2. How much longer is the study likely to continue?              Years              Months 
 
3. In an attached narrative provide a progress report.  Summarize all-important 
aspects of progress or results to date and if the study is to continue the reasons 
for the continuance.  An abstract or other report may be included.  Check if 
attached .  If not checked, explain below. 
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4. Did any “adverse event” occur during the course of this study, at any site since 
approval or the last Periodic Review, whichever was later?  Unless specifically 
modified by CORRC for your proposal an “adverse event” is any unfavorable and 
unintended diagnosis, symptom, sign (including an abnormal laboratory finding), 
syndrome or disease that either occurs during the research study, having been 
absent at baseline, or if present at baseline, now appears to be worse.  It also 
means any event that is otherwise reportable to a sponsor or co-sponsor of the 
research as an “adverse event.”    No  Yes (If yes, include in an 
attached narrative a summation of the adverse events, the actions taken 
as a result, etc.) 
 
5. Were there any unanticipated problems involving risk to subjects or others?   
No  Yes 
(If yes, explain in an attached narrative) 
 
6. Have there been any new significant findings (favorable or unfavorable) that might 
affect CORRC’s human subject risks/benefits analysis or which may otherwise 
influence subjects’ willingness to continue as subjects?   No  Yes (If yes, 
explain in an attached narrative.) 
 
7. Has the protocol been changed since its approval, or if later, since the last Periodic 
Review?  This includes, but is not limited to, changes to the subject population, 
recruitment and selection criteria, research site, recruitment methods or 
documents, the informed consent process, the informed consent documentation, 
and the methods for ensuring confidentiality.  No   Yes (If yes, provide 
the current version number and date of the protocol.  Make sure that a 
copy has been filed with the CORRC.  Also explain the changes in an 
attached narrative.) 
 
8. Attach clean copies of each informed consent document that is currently being 
used.  These will be returned with the appropriate approvals added. Check if 
attached .  If not checked explain. 
 
9. Have there been any changes in any subject’s capacity to give informed consent?
 No  Yes (In all instances attached a narrative that explains how 
capacity to give informed consent is monitored and if Yes is checked, 
provide details as to the changes that were noted.) 
 
10. Have current informed consent forms been obtained from all subjects?  No  
Yes. (If No, explain in an attached narrative.) 
 
10A.  Does each informed consent form include documentation that a clinical 
determination was made of the subject’s capacity to give informed consent?  
 No  Yes. (If No, explain in an attached narrative.) 
 
10B.  Attached narrative that explains how and where the informed consent forms 
are retained. 
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11. Attach an explanation as to how participation in the study impacts overall clinical 
care.  This explanation should address how and by whom decisions about a 
subject’s care are made and how communication is maintained between research 
and clinical staff involved in the subject’s treatment. 
 
12. Attach a summary (not to exceed 3 pages) of any additional information about the 
project that you want CORRC to consider in its Periodic Review. 
 
III. AVAILABLE PRESENT KNOWLEDGE 
 
1. Since approval or the last Periodic Review, whichever was later, have there been 
any material changes in the knowledge base that relate to the continued relevance 
of the study?                  No  Yes (If Yes, explain in an attached 
narrative the changes and why the study is still relevant. An updated 
bibliography may be attached if useful in responding to this question.) 
 
2. Since approval or the last Periodic Review, whichever was later, have there been 
any material changes in the knowledge base relevant to any of the interventions 
that are used in your study?  No  Yes (If Yes, explain in an attached 
narrative the changes and how they impact the risk/benefit of your 
study.  Also include a summary of all adverse events that you are aware 
of in other similar studies.) 
 
IV.  SIGNATURE 
 
 By signing this form I confirm that the information contained herein and all attachments 
are true to the best of my knowledge and belief. 
 
 
             
            Principal Investigator (SIGNATURE)                 Date 
 
 
SEND COMPLETED FORMS TO: 
Jeffrey Burke, Co-Chair 
Central Office Research Review Committee (CORRC) 
Department of Mental Health 
167 Lyman Street 
Westborough, MA  01581 
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ATTACHMENT 3 
 
HIPAA COMPLIANCE ADDENDUM FOR CONSENT FORMS 
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INSTRUCTIONS: 
 
The Health Insurance Portability and Accountability Act of 1996 (HIPAA) 
includes very specific requirements that research subjects must provide 
a written authorization for the use of their Protected Health Information 
(PHI).  All research subjects recruited after April 14, 2003, must have a 
HIPAA-compliant informed consent form and a specific HIPAA 
Authorization Form.   
 
This form is intended to be used for all studies which have been determined by the 
Central Office Research Review Committee to entail no more than minimal risk 
and do not have funding from an external source.    
 
You must use this HIPAA Authorization Form for all research subjects recruited after April 14, 2003, 
if: 
 
You do not already have an approved HIPAAA addendum for the consent form, or 
You do not use a consent form with the required HIPAA elements included. 
 
 
If you have questions, contact  
Jeffrey Burke, Co-Chair 
Central Office Research Review Committee (CORRC) 
508-616-3502 
Jeffrey.burke2@massmail.state.ma.us  
 
 
Thank you. 
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 RESEARCH SUBJECT’S AUTHORIZATION 
FOR RELEASE OF HEALTH INFORMATION FOR RESEARCH PURPOSES 
 
Name of Research Study:_______________________________________________ 
 
CORRC Number: ____________________ 
 
Subject’s Name: ______________________________________  
 
We want to use your private health information in this research study. The law requires 
us to get your authorization (permission) before we can use your information or share it 
with others for research purposes.  You can choose to sign or not to sign this 
authorization. However, if you choose not to sign this authorization, you will not be able 
to take part in the research study.  Whatever decision you make about this research study 
will not affect your access to care in any way. 
 
 
Section A:  Using and sharing your health information 
 
Who will be asked to give us your health information? 
 
The informed consent form that you are asked to sign contains detailed information about 
who will be asked to give us your health information.   You should read that section of the 
informed consent form carefully and if you have any questions, discuss this with the 
person who is presenting this form to you. 
 
Who will be able to use your health information for research? 
 
Only the researchers and research staff conducting this study will be able to 
use your health information for research purposes.  This study is not supported 
by funding from any outside party that will have access to your information.   
 
Who else will have access to your health information? 
 
We may also be asked or required by law to share your health information with the 
following people if they request it.  Once we give it to them, your information is no longer 
protected under the federal Privacy Rule.  However, its use and further disclosures remain 
limited as stated in your Informed Consent Form as part of the Central Office Research 
Review Committee oversight.  
 
o Department of Mental Health Central Office Research Review Committee, 
including the Human Protections Administrator, and its designees  
o Department of Mental Health   
o Study Safety Monitors 
o The Office of Human Research Protection and other governmental agencies 
that oversee research 
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Section B:  Description of information: 
 
(1)  What is the purpose of recording your health information?  
 Find out study eligibility (screening) 
• Data analysis of results (The Informed Consent Form includes a description of the 
purpose of this study.  If you have any questions about the purpose of the study 
you should discuss it with the person who is presenting this form to you.) 
• Study audit and oversight 
 
(2) What specific information will be collected? 
The informed Consent Form includes a detailed list of the health information that will 
be recorded in this study.  If you have any questions about what data will be collected 
you should discuss it with the person presenting this form to you.   
  
Section C:  General 
 
When does this Authorization Expire? 
 
 This authorization expires on:__________________________ 
 
Do you have the right to revoke this Authorization? 
You may revoke (take back) this authorization at any time.  To do this, you must ask the 
Principal Investigator for the names of the Privacy Officers at the institutions where we 
got your health information.  You must then notify those Privacy Officers in writing that 
you want to take back your Authorization.  If you do, we will still be permitted to use and 
share the information that we obtained before you revoked your authorization but we will 
only use and share your information the way the Informed Consent Form says. 
 
1. If you revoke this authorization, we may still need to share your health 
information if you have a bad effect (adverse event) during the research.   
 
Do You have access to the Information? 
You have the right to see your medical records, but you will not be allowed to 
review medical records in your research records until after the study is completed.   
……………………………………………………………………………………………………… 
 
I have read this information, and I will receive a signed copy of this form. 
 
____________________________________________________                                     ______________ 
Signature of research subject or personal representative   Date 
 
Printed name of personal representative: ______________________________________ 
 
Relationship to research subject: _______________________________________________ 
 
Please describe the personal representative’s authority to act on behalf of the subject:  
 
______________________________________________________________________________ 
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ATTACHMENT 4 
 
ADVERSE EVENT REPORTING INSTRUCTIONS AND FORM 
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COMMONWEALTH OF MASSACHUSETTS 
DEPARTMENT OF MENTAL HEALTH 
GUDELINES FOR THE REPORTING OF ADVERSE INCIDENTS RELATING 
TO RESEARCH 
 
The Department Research Review Committee must implement the following guidelines for 
the reporting of Adverse Events to research and ensure that they are also implemented by 
the Principal Investigator of any research protocol approved by it.  The Guidelines define 
“Adverse Event” and establishes when a Principal Investigator must report such events to 
the Department Research Review Committee and when the Committee must further report 
an event to designated Department officials.  To help ensure compliance, the Committee 
must provide a copy of the Guidelines to each Principal Investigator of an approved 
research protocol.   
 
DEFINITIONS: 
 
Adverse event* means any unfavorable and unintended diagnosis, symptom, sign 
(including an abnormal laboratory finding), syndrome or disease that either occurs 
during the research study, having been absent at baseline, or if present at baseline, 
now appears to be worse.  It also means any event that is otherwise reportable to a 
sponsor or co-sponsor of the research as an “adverse event.”   
 
Serious Adverse Event* means any untoward medical occurrence that (1) results 
in death; (2) is life threatening; (3) requires or prolongs hospitalization; (4) causes 
persistent or significant disability/incapacity; or (5) in the judgment of the 
investigator represents a significant hazard.  A life-threatening Adverse Event is an 
event that places a subject at immediate risk of death from the event as it occurred; 
a life threatening event does not include an event that, had it occurred in a more 
severe form, might have caused death, but as it actually occurred, did not create an 
immediate risk of death.   
 
*The Department Research Review Committee will ask every Principal 
Investigator to define “Adverse Event” for the purposes of his or her proposed 
study and to provide a plan for identifying, grading and reporting such events to the 
Committee.  The Committee might modify the above definitions for a particular 
study to ensure the protection of human subjects; providing, however, that the 
Committee shall only add (not delete) events to the definition of “Serious Adverse 
Event.” 
 
II.  PRINCIPAL INVESTIGATOR’S RESPONSIBILITIES 
 
A. Duty to Report.  The Principal Investigator must report all Adverse Events to 
the Chair of the Department Research Committee or to the Co-Chair that is 
designated by the Committee to receive such reports.  An Adverse Event must 
be reported within the time frames and in the format designated below. 
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B. Time Frames for Reporting.  Unless otherwise specified in the applicable 
research protocol as approved by the Department Research Review Committee, 
the Principal Investigator must report Adverse Events as follows: 
 
1. Serious Adverse Event.  A Serious Adverse Event must be reported verbally 
as soon as it is reasonably possible and in writing by the next business day 
following the Event.  The attached report form, or a similar form approved by 
the Department Research Review Committee, shall be used for this purpose.  
Serious Adverse Events, both related and unrelated to the research, must be 
reported.  
 
2. Adverse Event that is Not a Serious Adverse Event.  A summation of all 
Adverse Events that do not qualify as Serious Adverse Events must be provided 
to the Chair of the Committee by the Principal Investigator every four (4) 
months, or as otherwise determined appropriate by the Department Research 
Review Committee.  The summation shall be in the format designated by the 
Department Research Review Committee.  At a minimum the following 
information shall be provided for each Adverse Event: date, degree of 
seriousness, relationship to the research, if expected or not, and the actions 
taken.  
 
C.  Filing a Summation for Each Continuing Review.  Whenever the Principal 
Investigator is required to submit a Department Periodic Review Form, or when 
otherwise requested by the Department Research Review Committee, the 
Principal Investigator shall submit a summation of all Adverse Events (serious 
and non-serious) that have occurred to date.  The summation shall be in the 
format designated by the Department Research Review Committee. 
 
D.  Addressing Impact on Subjects.  When reporting a Serious Adverse Event to 
the Department Research Review Committee, the Principal Investigator must 
address the need and method to communicate pertinent information to research 
subjects; the need to redesign or amend the research protocol, and whether or 
not a change in the description of risk is warranted in the protocol and the 
consent form. 
 
E.  Critical Incident Reporting.  If the research protocol is being conducted at a 
Department Facility or a Department operated or contracted program, the 
Department’s Critical Incident Reporting Protocol and guidelines must be 
complied with in addition to the requirements set forth in these guidelines.  
These guidelines do not in any way amend or replace those required by the 
Department’s Critical Incident Reporting Protocol and guidelines.   
 
III.  RESEARCH REVIEW COMMITTEE’S RESPONSIBLITLIES 
 
A.  Duty of the Chair to Notify Other Department Officials.  Upon receipt of a 
Serious Adverse Event report, the Chair of the Department Research Review 
Committee shall notify the Deputy Commissioner of Clinical and Professional 
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Services and the Area Medical Director of the Area in which the Event 
occurred. The Chair shall also forward copies of the summation of Adverse 
Events that are not Serious and of all Serious Adverse Events to the Deputy 
Commissioner of Clinical and Professional Services and the Applicable Area 
Medical Director(s) within such time frames as the Deputy Commissioner 
shall designate.   
 
B.  Duty of the Chair to Notify the Full Committee.  The chair shall report all 
Serious Adverse Events to the full Committee within the time frame he or she 
deems appropriate; provided, however such reports shall not be made later than 
the next scheduled meeting.  The Chair shall consider calling a special meeting 
of the Committee to address a Serious Adverse Event.   
 
C.  Evaluation and Committee Action.  It is the duty of the Committee to 
evaluate all Serious Adverse Event reports and all Adverse Event summations 
that it receives.  Such assessments shall be done promptly.  In evaluating a 
Serious Adverse Event report, and/or a summation of Adverse Events that are 
not Serious Adverse Events, and/or a summation of all Adverse Events, the 
Department Research Review Committee shall consider the following: (a) the 
seriousness of the Event(s); (b) the relationship of the Event(s) to the research; 
(c) whether the Event(s) was expected or not; (d) appropriateness of the 
action(s) taken or proposed by the Principal Investigator, and (e) need to inform 
current or future subjects either by change in the protocol and informed consent 
documents or by other written or verbal communication.  In its response to the 
report of any Adverse Event the Department Research Review Committee is 
authorized to take such action as it deems necessary to safeguard research 
subjects.  This includes, but s not limited to, modifying the protocol, changing 
the informed consent procedure or form(s); suspending subject enrollment; or 
terminating the protocol.   
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Commonwealth of Massachusetts 
Department of Mental Health 
Central Office Research Review Committee 
 
Serious Adverse Event Report Form 
 
 
1. PRINCIPAL INVESTIGATOR INFORMATION: 
 
Protocol Number: ______________________________________________________________ 
Protocol Title: _________________________________________________________________ 
Principal Investigator: __________________________________________________________ 
Telephone Number: _______________________ Fax Number: _________________________ 
Email Address: ________________________________________________________________  
Mailing Address: _______________________________________________________________ 
______________________________________________________________________________ 
 
 
 
2. SUBJECT INFORMATION: 
 
Birth Date: ______________________  Gender: [ ] M  [ ] F 
DMH Client:  [ ] Y [ ] N 
Current Status of the Client: 
_________________________________________________________________________ 
_______________________________________________________________________________ 
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________ 
_______________________________________________________________________________ 
_______________________________________________________________________________ 
 
 
3. EVENT INFORMATION 
 
Date Event Started: __________________ Date Event Ended: _________________________ 
Site of Event: __________________________________________________________________ 
Event Summary Description.  Give a brief description of the circumstances leading to the adverse 
event, describe its course (include diagnosis/syndrome, component signs and symptoms); and 
indicate any unscheduled diagnostic procedures or treatment measures and corresponding dates.  
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
 
Death  [ ]Yes [ ] No       Hospitalization  [ ] Yes [ ] No    Life Threatening  [ ] Yes [ ]No 
Disability  [ ]Yes [ ] No 
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4. RELATIONSHIP OF SERIOUS ADVERSE EVENT TO RESEARCH 
[ ] Unrelated (Clearly not related to the research)     
 
[ ] Unlikely (Doubtfully related to the research) 
 
[ ] Possible (May be related to the research) 
 
[ ] Probable (Likely related to the research) 
 
[ ] Definite (Clearly related to the research) 
 
Have similar adverse events occurred on this protocol? [ ] Yes [ ] No 
If “Yes,” how many? _____________ Please describe: ________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
 
 
5. CORRECTIVE ACTION: 
 
What steps do you plan to take as a result of the adverse event reported above?  Provide 
documentation to the Research Review Committee for review and approval of any of the 
steps checked below: 
 
[ ] no action required   [ ] terminate the protocol 
[ ] amend the consent procedures [ ] inform current subjects 
[ ] amend the protocol   [ ] other (describe below) 
[ ] suspend the protocol  
______________________________________________________________________________ 
______________________________________________________________________________ 
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
___________________________________________________________________________ 
______________________________________________________________________________ 
 
 
 
 
Investigator Signature _____________________________ Date ____________________ 
 
 
 
 
 
 
 
 
